Neuren Pharmaceuticals Limited (ASX: NEU)

Neuren Pharmaceuticals Cash Flow Statement

Financials in millions AUD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Net Income	117.29	157.08	0.18	-7.79	-9.19	-10.82
Depreciation & Amortization	0.02	0.02	0.01	0.01	0.01	0
Loss (Gain) From Sale of Investments	-0.26	1.53	0.7	-	-	0.26
Stock-Based Compensation	2.66	2.93	1.99	0.84	0.39	-
Other Operating Activities	0.41	0.14	0.18	-0.4	0.72	-0.14
Change in Accounts Receivable	-4.28	-15.55	0.19	-2.51	-0.2	0.39
Change in Accounts Payable	1.38	2.44	0.34	-0.11	0.19	-1.41
Operating Cash Flow	119.51	184.93	3.6	-9.97	-8.08	-11.72
Operating Cash Flow Growth	120.12%	5038.23%	-	-	-	-
Capital Expenditures	-0.03	-0.04	-0.02	-0.01	-0.01	-0.01
Investment in Securities	-163.32	-211.45	-	-	-	-
Investing Cash Flow	-163.34	-211.49	-0.02	-0.01	-0.01	-0.01
Issuance of Common Stock	4.19	3.64	-	23.28	20.22	1.86
Other Financing Activities	-0.02	-0.02	-0	-1.11	-1.08	-
Financing Cash Flow	4.17	3.62	-0	22.18	19.14	1.86
Foreign Exchange Rate Adjustments	3.84	-0.15	-0.18	0.4	-0.71	0.14
Net Cash Flow	-35.82	-23.09	3.4	12.6	10.34	-9.73
Free Cash Flow	119.49	184.89	3.58	-9.98	-8.08	-11.73
Free Cash Flow Growth	120.19%	5064.39%	-	-	-	-
Free Cash Flow Margin	61.80%	79.71%	23.22%	-312.17%	-1127.48%	-2369.90%
Free Cash Flow Per Share	0.91	1.41	0.03	-0.08	-0.08	-0.12
Cash Income Tax Paid	33.28	-0.88	-1.39	-2.52	-0.49	-0.45
Levered Free Cash Flow	98.45	152.97	2.59	-6.76	-5.12	-5.83
Unlevered Free Cash Flow	98.45	152.97	2.59	-6.76	-5.12	-5.83
Change in Net Working Capital	1.19	-25.53	-1.07	2.46	0.01	-1.1

Source: S&P Capital IQ. Standard template. Financial Sources.